April 23, 2021 Who will be the medical cannabis patients in Europe? – Prohibition Partners
In order to serve the medical cannabis patient people in Europe, operators require a knowledge of who the patients are and why they rely on those medications. Prohibition Partners has summarised the accessible data under, and provided more research in our current European Cannabis Report.
Prohibition Partners has gathered data for European clinical cannabis patients from national government agencies and individual research groups to investigate high-level statistics about patients being prescribed medical cannabis. Among the leading sources of information in Europe is Project Twenty21, conducted by Drug Science in the UK, which will be a patient registry that’aims to create the UK’s largest body of evidence for the efficacy and tolerability of health cannabis’ by easing patient access and publishing anonymised data.
Prohibition Partners talked to Dr Anne Katrin Schlag, head of research at Drug Science, about the information ahead of an upcoming book on UK patients at the Journal of Psychopharmacology. She explained that:
‘Our patient population comprises a massive age range (more or less by 18–80 years old). Their consistently high levels of comorbidity and very low quality of life demonstrate precisely how unwell a lot of them are. So, almost any stereotypes of medicinal cannabis consumers as being 20-something, wholesome recreational consumers searching for a legal source could not be farther from the truth’ .
Drug Science also provided some updated info about the UK for the research below.
Medical cannabis demonstrates promise in handling a wide range of ailments, being a modulator of the endocannabinoid system, and using a safe and powerful anti inflammatory profile. While cannabinoid drugs are qualified for a limited set of states, such as Epidiolex for rare epilepsies, physicians and patients make use of these medications to cover a lot more conditions.
Producers of medical cannabis for the European market should pay attention to the conditions for which cannabis is being prescribed around the continent. The needs of patients differ widely by illness, such as where CBD/Epidiolex® is more helpful for epileptic patients, THC is more useful for the reduction of nausea. Below are the signs of which medical cannabis goods are prescribed per state.
Pain is definitely the most commonly cited reason for physicians to prescribe medical cannabis. Chronic pain affects as many as 1 in 3 individuals in developed countries, normally defined as pain happening most days or every day for 2 months. European tendencies are similar with North America in medical cannabis being prescribed most frequently for pain.
‘Pain and anxiety disorders were the two most frequent disorders in both men and women; women were more likely to report a primary condition of chronic pain (61.5% vs 51.0percent ) while men were more likely to report anxiety disorders (38.0% versus 23.8percent ).’
Medical cannabis patients trying to deal with pain vary in their desire depending on intensity of pain and frequency of usage. Generally speaking, patients who have pain prefer cannabinoid drugs with balanced and high amounts of THC and CBD, using high-frequency consumers preferring high THC and reduced CBD. This is represented by the types of health cannabis currently available in Europe, with most countries with a wider array of medicines with high THC and balanced THC:CBD compared to high CBD alone.
The typical age of medical cannabis patients in Europe is comparable to that of the North American patient people, if slightly elderly. In the largest marketplace in Europe, Germany; the average age of medical cannabis consumers in the nation is 54. Denmark and Italy are noteworthy for having an people of older medical cannabis patients at a mean of ~57 and 58 respectively. Early data from Job Twenty21 indicates that the patient groups in the UK are somewhat younger than in other European countries, with a mean age of approximately 39.
People of different age groups are known to prefer distinct medical cannabis solutions. For instance, data from the official poll of German patients suggest that the typical age of medical cannabis patients with blossoms is 46, although the average for infusion usage is 57. The Federal Institute for Drugs and Medical Devices (BfArM) in Germany has noted that lots of prescriptions for cannabis blossom go awry, which could skew the information because these patients are known to be often male and marginally younger than patients utilizing different goods.
The information on gender of medical cannabis patients in Europe indicate that the equilibrium is more between male and female than in North America, in which the patient population is majority male. Denmark and Italy are notable for their patient populations with a sizable female majority at 62% and 63% respectively. Based on data from Job Twenty21, the UK’s patient population is more akin to this in North America in terms of gender balance, having a 66% majority being man at April annually. Germany and the UK are the only countries where information for non-binary patients are accessible and thus far approximately 0.1% and 0.6percent of patients recognize as such in each and every nation.
Much like demographics, gender plays a role in patient product decision. In Germany for instance, 68 percent of patients receiving blossom are male, whereas females dominate the use of dronabinol (58%), Sativex® (54%) and extracts (54%), as reported in the polls of the BfArM.
The information presented here reflects a lot of the available information on patients in Europe. It should be mentioned that the data represent a small part of the complete patient population on the continent, with countless people nevertheless self-prescribing medical cannabis and huge swathes of patients not being included in printed data, like the population in Switzerland. As these data become available, Prohibition Partners will offer pertinent upgrades as part of ongoing efforts to encourage patient needs being met in Europe.
Prohibition Partners dive more deeply in this and other subjects in their recently released European Cannabis Report: 6th Edition that looks at social, economic, regulatory and health tendencies such as:
- The progress of medical cannabis gain in Europe
- The progress of adult-use initiatives
- The introduction of European capital markets to cannabis
- The impact of COVID-19 on patient access and the industry at large
- The patients in Europe along with the goods they are utilizing
- The tendencies in product formulation towards extracts and isolates
- The diversification of the supply chain in Europe